
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Montreal - Diagnosing unusual sexually transmitted infections can be a unique challenge, particularly for physicians lacking expertise in this area.






